News Rumour confirmed as Lilly buys Ventyx for $1.2 billion Eli Lilly has agreed a $1.2bn takeover of Ventyx Bio and its clinical-stage drugs for inflammatory and cardiometabolic diseases.
News Lilly taps Nimbus for another obesity candidate For a second time, Eli Lilly has turned to Boston biotech Nimbus Therapeutics to add a potential weight loss therapy to its pipeline.
News Novo Nordisk launches Wegovy pill at $149 a month Novo Nordisk has followed through on its pledge for a swift launch of the Wegovy pill for weight loss, and revealed its pricing for self-payers.
News Novo Nordisk gets FDA okay for Wegovy pill The FDA has delivered a gift to Novo Nordisk ahead of the holiday season, with the prompt approval of its Wegovy pill.
News Lilly points to long-lasting weight loss with orforglipron Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.
News Lilly's obesity triple pulls off 29% weight loss in trial Eli Lilly has ramped up the competition in weight-loss therapies by reporting the first pivotal data with its triple therapy retatrutide.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
